Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The PLAU-ITGB1-TGF-β axis orchestrates spatiotemporal reprogramming of fibroblasts at the invasive front to drive dual immunosuppressive niche and immunotherapy resistance in oral squamous cell carcinoma.

Created on 17 Jul 2026

Authors

Yili Xiong, Shaopeng Liu, Lianyu Zhao, Xinze Liu, Hanzhi Zhang, Haoran Wang, Dongsheng Zhang, Changlong Wang, Haiwei Wu

Published in

Cell death & disease. Jul 16, 2026. Epub Jul 16, 2026.

Abstract

The initiation and progression of cancer are driven by the dynamic interplay between somatic mutations and the tumor microenvironment. Identifying core cell populations driving malignant transformation and understanding the intercellular interactions within the tumor microenvironment are, therefore, crucial for early diagnosis and effective treatment. Here, we construct a spatiotemporal atlas of oral squamous cell carcinoma (OSCC) progression by integrating multi-omics approaches. Our analysis reveals that the critical driver gene PLAU activates the TGF-β pathway via ITGB1, thereby promoting the conversion of fibroblasts into the COL11A1⁺ fibroblast (COL11A1⁺ Fib). These specialized fibroblasts remodel the extracellular matrix (ECM), collectively establishing an immunosuppressive niche composed of malignant epithelial cells, COL11A1+ Fib, and regulatory T cells (Tregs). Importantly, targeting COL11A1+ Fib alleviates this immunosuppressive niche and curbs OSCC progression. Our findings underscore the potential of COL11A1+ Fib as a predictive biomarker, especially in combination with immunotherapy. Collectively, this work demonstrates that the PLAU-ITGB1-TGF-β axis drives the formation of an Epi-COL11A1+ Fib-Treg immunosuppressive niche that fuels OSCC malignancy.

PMID:
42463632
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement